Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

R. J. W. van Kampen; B. L. T. Ramaekers; D. J. A. Lobbezoo; M. de Boer; M. W. Dercksen; F. van den Berkmortel; T. J. Smilde; A. J. van de Wouw; F. P. J. Peters; J. M. G. van Riel; N. A. J. B. Peters; V. C. G. Tjan-Heijnen; M. A. Joore

doi:10.1016/j.ejca.2017.01.027

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

R. J. W. van Kampen, B. L. T. Ramaekers, D. J. A. Lobbezoo, M. de Boer, M. W. Dercksen, F. van den Berkmortel, T. J. Smilde, A. J. van de Wouw, F. P. J. Peters, J. M. G. van Riel, N. A. J. B. Peters, V. C. G. Tjan-Heijnen, M. A. Joore^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	238-246
Number of pages	9
Journal	European Journal of Cancer
Volume	79
DOIs	https://doi.org/10.1016/j.ejca.2017.01.027
Publication status	Published - Jul 2017

Keywords

Metastatic breast cancer
Bevacizumab
Cost-effectiveness analysis
Real-world
Trial based
Cost-benefit analysis
RANDOMIZED PHASE-III
1ST-LINE TREATMENT
PLUS DOCETAXEL
PACLITAXEL
WOMEN

Access to Document

10.1016/j.ejca.2017.01.027

Cite this

van Kampen, R. J. W., Ramaekers, B. L. T., Lobbezoo, D. J. A., de Boer, M., Dercksen, M. W., van den Berkmortel, F., Smilde, T. J., van de Wouw, A. J., Peters, F. P. J., van Riel, J. M. G., Peters, N. A. J. B., Tjan-Heijnen, V. C. G., & Joore, M. A. (2017). Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European Journal of Cancer, 79, 238-246. https://doi.org/10.1016/j.ejca.2017.01.027

van Kampen, R. J. W. ; Ramaekers, B. L. T. ; Lobbezoo, D. J. A. ; de Boer, M. ; Dercksen, M. W. ; van den Berkmortel, F. ; Smilde, T. J. ; van de Wouw, A. J. ; Peters, F. P. J. ; van Riel, J. M. G. ; Peters, N. A. J. B. ; Tjan-Heijnen, V. C. G. ; Joore, M. A. / Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients : a study of the Southeast Netherlands Breast Cancer Consortium. In: European Journal of Cancer. 2017 ; Vol. 79. pp. 238-246.

@article{1d0bf68a8d5d49c0b492928dbfe99c2e,

title = "Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium",

keywords = "Metastatic breast cancer, Bevacizumab, Cost-effectiveness analysis, Real-world, Trial based, Cost-benefit analysis, RANDOMIZED PHASE-III, 1ST-LINE TREATMENT, PLUS DOCETAXEL, PACLITAXEL, WOMEN",

author = "{van Kampen}, {R. J. W.} and Ramaekers, {B. L. T.} and Lobbezoo, {D. J. A.} and {de Boer}, M. and Dercksen, {M. W.} and {van den Berkmortel}, F. and Smilde, {T. J.} and {van de Wouw}, {A. J.} and Peters, {F. P. J.} and {van Riel}, {J. M. G.} and Peters, {N. A. J. B.} and Tjan-Heijnen, {V. C. G.} and Joore, {M. A.}",

year = "2017",

month = jul,

doi = "10.1016/j.ejca.2017.01.027",

language = "English",

volume = "79",

pages = "238--246",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

van Kampen, RJW, Ramaekers, BLT , Lobbezoo, DJA , de Boer, M, Dercksen, MW, van den Berkmortel, F, Smilde, TJ, van de Wouw, AJ, Peters, FPJ, van Riel, JMG, Peters, NAJB, Tjan-Heijnen, VCG & Joore, MA 2017, 'Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium', European Journal of Cancer, vol. 79, pp. 238-246. https://doi.org/10.1016/j.ejca.2017.01.027

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients : a study of the Southeast Netherlands Breast Cancer Consortium. / van Kampen, R. J. W.; Ramaekers, B. L. T.; Lobbezoo, D. J. A.; de Boer, M.; Dercksen, M. W.; van den Berkmortel, F.; Smilde, T. J.; van de Wouw, A. J.; Peters, F. P. J.; van Riel, J. M. G.; Peters, N. A. J. B.; Tjan-Heijnen, V. C. G.; Joore, M. A.

In: European Journal of Cancer, Vol. 79, 07.2017, p. 238-246.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients

T2 - a study of the Southeast Netherlands Breast Cancer Consortium

AU - van Kampen, R. J. W.

AU - Ramaekers, B. L. T.

AU - Lobbezoo, D. J. A.

AU - de Boer, M.

AU - Dercksen, M. W.

AU - van den Berkmortel, F.

AU - Smilde, T. J.

AU - van de Wouw, A. J.

AU - Peters, F. P. J.

AU - van Riel, J. M. G.

AU - Peters, N. A. J. B.

AU - Tjan-Heijnen, V. C. G.

AU - Joore, M. A.

PY - 2017/7

Y1 - 2017/7

KW - Metastatic breast cancer

KW - Bevacizumab

KW - Cost-effectiveness analysis

KW - Real-world

KW - Trial based

KW - Cost-benefit analysis

KW - RANDOMIZED PHASE-III

KW - 1ST-LINE TREATMENT

KW - PLUS DOCETAXEL

KW - PACLITAXEL

KW - WOMEN

U2 - 10.1016/j.ejca.2017.01.027

DO - 10.1016/j.ejca.2017.01.027

M3 - Article

VL - 79

SP - 238

EP - 246

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

van Kampen RJW, Ramaekers BLT , Lobbezoo DJA , de Boer M, Dercksen MW, van den Berkmortel F et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European Journal of Cancer. 2017 Jul;79:238-246. https://doi.org/10.1016/j.ejca.2017.01.027